Published: January 2013
|Formats||Member Price||Nonmember Price|
|Individual Download||$99 / €80||$405 / €330|
|Which format is right for me?|
Recent survey results show that the pharmaceutical companies often take an overly conservative approach to NIMPs (or Non-IMPs) due to regulatory and operational ambiguity. This can lead to unnecessary expenses and process steps, which can needlessly complicate clinical trials.
The ISPE Good Practice Guide: Harmonizing the Definition and Use of Non-Investigational Medicinal Products (NIMPs) aims to provide practical operational guidance and drive a consistent industry approach to the use of NIMPs. The Guide contains criteria for classifying NIMPs and an overview of current NIMP regulatory requirements.
This in-depth Guide will help you properly manage NIMPs by providing guidance on:
Design Considerations for WFI Distillation Systems Part 4
Thursday, 26 May 2016 13.05
Direct Access to Quality Manufacturing Experts
Wednesday, 25 May 2016 13.05
Broadening Pharmaceutical Training Footprint in Europe
Tuesday, 24 May 2016 19.05